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ORIGINAL RESEARCH

Maternal Cardiac Output and Fetal Doppler Predict Adverse Neonatal
Outcomes in Pregnant Women With Heart Disease
Rachel M. Wald, MD; Candice K. Silversides, MD, SM; John Kingdom, MD; Ants Toi, MD; Cathy S. Lau, RDCS, CRCS; Jennifer Mason, RN;
Jack M. Colman, MD; Mathew Sermer, MD; Samuel C. Siu, MD, SM, MBA

Background-—The mechanistic basis of the proposed relationship between maternal cardiac output and neonatal complications in
pregnant women with heart disease has not been well elucidated.
Methods and Results-—Pregnant women with cardiac disease and healthy pregnant women (controls) were prospectively followed
with maternal echocardiography and obstetrical ultrasound scans at baseline, third trimester, and postpartum. Fetal/neonatal
complications (death, small-for-gestational-age or low birthweight, prematurity, respiratory distress syndrome, or intraventricular
hemorrhage) comprised the primary study outcome. One hundred and twenty-seven women with cardiac disease and 45 healthy
controls were enrolled. Neonatal events occurred in 28 pregnancies and were more frequent in the heart disease group as
compared with controls (n=26/127 or 21% versus n=2/45 or 4%; P=0.01). Multiple complications in an infant were counted as a
single outcome event. Neonatal complications in the heart disease group were small-for-gestational-age/low birthweight (n=18),
prematurity (n=14), and intraventricular hemorrhage/respiratory distress syndrome (n=5). Preexisting obstetric risk factors
(P=0.003), maternal cardiac output decline from baseline to third trimester (P=0.017), and third trimester umbilical artery Doppler
abnormalities (P<0.001) independently predicted neonatal complications and were incorporated into a novel risk index in which 0,
1, and >1 predictor corresponded to expected complication rates of 5%, 30%, and 76%, respectively.
Conclusions-—Decline in maternal cardiac output during pregnancy and abnormal umbilical artery Doppler ﬂows independently
predict neonatal complications. These ﬁndings will enhance the identiﬁcation of higher risk pregnancies that would beneﬁt from
close antenatal surveillance. ( J Am Heart Assoc. 2015;4:e002414 doi: 10.1161/JAHA.115.002414)
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I

ncreasing numbers of women with heart disease are
reaching reproductive age, attributable in large part to
advances in diagnosis and treatment in early life.1,2 In
contemplating pregnancy, women with heart disease seek
information not only regarding maternal, but also regarding
neonatal outcomes of pregnancy. We and others have
demonstrated that pregnant women with heart disease carry
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an increased risk of adverse maternal and neonatal outcomes.
Speciﬁcally, poor functional class and left heart obstructive
disease in the mother have been identiﬁed as independent
predictors of neonatal compromise.3–6
It has been postulated that a major mechanistic link
relating maternal heart disease with complications in the fetus
or neonate is uteroplacental insufﬁciency due to inadequate
maternal cardiac output.6–9 More than 40 years ago, Ueland
and colleagues measured cardiac output in a small group of
women with valvular heart disease who underwent cardiac
catheterization at various points during and after pregnancy.9
Although they examined a group that was likely highly
selected and antepartum data collection was incomplete, their
study suggested that insufﬁcient incremental increase in
maternal cardiac output occurs in pregnant women with
valvular heart disease. In contrast, a small study evaluating
cardiac output using echocardiography in 29 pregnant women
with congenital heart disease found that there was no
statistically signiﬁcant difference in cardiac output in women
with hypertension and/or small-for-gestational-age offspring.10 A systematic examination of cardiac output and its
relationship to pregnancy outcomes in a sizable population of
Journal of the American Heart Association
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because their relatively late stage in pregnancy would
preclude establishment of cardiac output prior to peak
changes in cardiac output that are anticipated early in the
third trimester.9 We also excluded women transferred for
inpatient care, those referred for termination of pregnancy,
and those unwilling/unable to give informed consent.
A concurrent control group of women without heart
disease was recruited from the general obstetric program at
the same hospital, which is co-located with the maternal
cardiac clinic and in which the same obstetricians provided
care for both the study and the control cohorts, in order to
ensure consistency in clinical practice and data collection
among all women. Control women were included if they
presented for obstetric care prior to 22 weeks gestation and
were deemed “low risk” (ie, absence of identiﬁable obstetric
risk factors or medical conditions). We applied the same
exclusion criteria as for the study group. If a woman recruited
into the control group was found to have structural heart
disease or another signiﬁcant medical condition, or if a fetal
abnormality was identiﬁed on obstetrical ultrasound, she was
withdrawn from the study and was referred for medical care
as appropriate. This study protocol received institutional
research ethics approval and all subjects gave informed
written consent.
Demographic and obstetric data collected in both heart
disease and control groups included the following: age,
baseline weight, height, gestational age, parity status, maternal smoking and/or alcohol consumption, and the presence of
obstetric risk factors for complications in offspring (history of
premature delivery or rupture of membranes, incompetent
cervix, cesarean section, antepartum bleeding >12 weeks
gestation, febrile illness, and/or uteroplacental abnormalities).4 In the heart disease group, the following data were also
recorded: type of cardiac lesion, past history of stroke, heart
failure, or arrhythmia, prior cardiac surgery or interventions,
baseline New York Heart Association (NYHA) functional class,
and nature of cardiovascular medications and cyanosis
(oxygen saturation <90%). Comorbid conditions (ie, pulmonary
disease, thyroid dysfunction, hypertension, diabetes mellitus,
and/or systemic lupus erythematosus)6 were documented if
present and were screened for with the same rigor in control
and study patients.

Methods
Study Design and Patient Population

Maternal Echocardiography

This prospective study enrolled women with heart disease
referred to Mount Sinai Hospital in Toronto, Ontario, Canada
for obstetric care. Heart disease was deﬁned as the presence
of structural cardiac abnormalities (excluding mitral valve
prolapse with ≤mild regurgitation) and/or symptomatic cardiac arrhythmia requiring treatment prior to pregnancy. We
excluded women who presented after 22 weeks gestation

All subjects underwent echocardiographic studies at 3 deﬁned
time points using an iE33 echocardiography machine (Philips
Medical Systems, Bothell, WA): (1) a baseline study
≤26 weeks gestation (prior to expected peak augmentation
of cardiac output), (2) a third-trimester study ≥27 weeks
gestation (corresponding to the anticipated peak in cardiac
output), and (3) a postpartum study at least 6 weeks following

DOI: 10.1161/JAHA.115.002414
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women with a spectrum of heart disease has not been
performed. Nevertheless, indirect evidence suggests that a
relationship may exist between impaired maternal cardiac
output and offspring outcomes in women with cardiac
disease. In women with structurally normal hearts, lower
maternal cardiac output, determined echocardiographically,
has been associated with intrauterine growth restriction.11
Some pregnant women with obstructive left heart disease do
not display the increase in transvalvular gradients on
echocardiography that would be expected with advancement
of pregnancy if anticipated augmentation of cardiac output by
30% to 50% were actually occurring in those women.12,13
Furthermore, there is an established association between
cardiac conditions that limit cardiac output including severe
left heart valvular stenosis and cardiomyopathy, and
increased frequency of neonatal complications.7,14,15
Although maternal cardiac hemodynamics have not been
adequately characterized in pregnant women with heart
disease, uteroplacental Doppler ﬂow patterns have recently
been described in women with congenital heart disease.
Pieper and Balci and colleagues reported abnormal umbilical
artery and uterine artery Doppler waveforms in women with
congenital heart disease, as well as its association with
complications in offspring.16 While direct measurements of
maternal cardiac output were not provided, they reported that
markers of impaired ventricular function and cardiovascular
adaptation were associated with abnormal umbilical artery
indices.16 These observations extend previous ﬁndings that
neonatal event rates in women with cardiovascular risk
factors for such events are highest in those women who also
have preexisting obstetric (noncardiac) risk factors.4
To address current deﬁciencies in knowledge, speciﬁcally
the relationship between maternal cardiac output, uteroplacental ﬂow characteristics, and pregnancy outcomes, we
prospectively and serially characterized maternal cardiac
output and Doppler ﬂow patterns at umbilical and uterine
arteries in pregnant women with heart disease. We hypothesized that insufﬁcient maternal cardiac output and fetal ﬂow
abnormalities would be predictive of complications in
offspring.
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Fetal and Uteroplacental Ultrasonography
Fetal ultrasound imaging was performed by certiﬁed obstetrical sonographers on 2 occasions during the antepartum
period (early, ≤26 weeks gestation and late, ≥27 weeks
gestation) using an iU22 ultrasound system (Philips Medical
Systems). On all ultrasound studies, pulsed Doppler proﬁles of
the free loop of the umbilical arteries and the proximal uterine
arteries were obtained and pulsatility index was calculated
[PI]; for the uterine artery waveforms, the presence or
DOI: 10.1161/JAHA.115.002414

absence of early diastolic notching was also recorded.24,25
Umbilical artery recordings were performed in the absence of
fetal breathing or fetal movements according to accepted
standards of practice.26 The proximal uterine arteries were
located at their crossover point with the external iliac arteries,
using color ﬂow mapping. Doppler waveforms were analyzed
from 3 consecutive beats and care was taken to ensure that
the angle of insonation did not exceed 30°. Details of the
protocol employed at our institution for obstetric ﬂow
analyses have been previously published.27

Outcome Events
A study coordinator blinded to imaging results recorded and
veriﬁed all clinical outcome events using delivery records,
clinic charts, and hospital health records. The primary study
outcome consisted of fetal or neonatal complications deﬁned
as low birth weight (small-for-gestational-age if birthweight
was <10th percentile for gestational age or if absolute
birthweight was <2500 g), premature delivery (delivery
<37 weeks gestation), respiratory distress syndrome, intraventricular hemorrhage, fetal demise (death >20 weeks
gestation), or neonatal death (death within 30 days of
delivery). Cranial ultrasound scans for the diagnosis of
intraventricular hemorrhage are routinely performed at our
center on infants <1500 g at birth, on those with documented
abnormalities on antenatal ultrasound scan, and on infants in
whom neurologic abnormalities are identiﬁed after birth.

Statistical Analysis
Statistical analysis was performed using SPSS for Windows
(Version 22.0; IBM Corp, Armonk, NY). Data were presented
as meansSD or proportions; if data were not normally
distributed, median values with ranges were provided. For
non-normally distributed data, variance-stabilizing transformation was utilized prior to statistical testing. Two-tailed P
values were calculated and level of signiﬁcance was set at
0.05, unless otherwise speciﬁed.
Univariate analyses of potential predictors of the primary
outcome in the heart disease group were performed using
Student t, v2, and Fisher Exact tests, wherever appropriate.
Candidate variables included baseline demographics (age,
parity, obstetric risk factors), smoking history, comorbid
conditions (thyroid, pulmonary, systemic lupus erythematosus, hypertension, or diabetes mellitus), cardiovascular complications prior to or during current pregnancy (stroke,
transient ischemic attack, pulmonary edema/heart failure,
sustained arrhythmia requiring treatment), NYHA functional
class, nature of cardiac medications, echocardiographic
indices of stenosis and/or regurgitation, any ventricular
systolic dysfunction, maternal cardiac output, Doppler-derived
Journal of the American Heart Association

3

ORIGINAL RESEARCH

Downloaded from http://ahajournals.org by on June 21, 2022

delivery (at which point the majority of the hemodynamic
changes related to pregnancy are anticipated to have returned
to baseline).17 Ventricular and valvular function were evaluated according to standardized guidelines.18–20 A single
dedicated cardiac research sonographer (CSL) blinded to
patient characteristics and study order performed off-line
echocardiographic analysis. To calculate stroke volume and
cardiac output, pulse wave Doppler imaging with the highest
left ventricular outﬂow tract (LVOT) velocity from either the
apical or suprasternal views was recorded and LVOT diameter
was measured from the parasternal long axis view during
systole.21 If LVOT pulse wave Doppler was not feasible due to
elevated subaortic velocities (present in 12 patients with
valvular aortic stenosis and/or LVOT obstruction related to
hypertrophic cardiomyopathy), then the pulse wave Doppler
proﬁle was recorded at the pulmonary valve and pulmonary
annulus diameter was measured from the parasternal short
axis view. For each measured parameter, 5 consecutive
cardiac cycles were recorded (10 consecutive cardiac cycles
in the presence of atrial ﬁbrillation or frequent ectopics). The
same observer remeasured cardiac output in a random
sample of 12 studies to establish intraobserver variability,
which was deﬁned as the percentage error between paired
measurements (percentage error=[SD between 2 measurements9100%]/[mean of the 2 measurements])22; a decrease
in cardiac output was therefore considered signiﬁcant if
values exceeded established intraobserver measurement
variability (percentage error was 9% and 23% for the aortic
and pulmonary valve cardiac output, respectively).
Signiﬁcant left heart obstructive disease was deﬁned as
mitral valve area <2.0 cm2, aortic valve area <1.5 cm2, or
peak LVOT gradient >30 mm Hg in the case of subaortic
stenosis, as previously described.6 Signiﬁcant pulmonary
stenosis was deﬁned as a maximum instantaneous gradient
>3 m/s and signiﬁcant tricuspid stenosis as a mean gradient
>5 mm Hg.20 Moderate or severe valvular regurgitation was
considered signiﬁcant.19 Systemic ventricular ejection fraction was calculated using biplane method of disks for
morphologic left ventricles and was estimated visually for
morphologic right ventricles; ejection fraction<40% was
considered signiﬁcant systolic dysfunction.6,18,23
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Results

women chose not to participate, and 4 women were
withdrawn from the study (fetal demise before 20 weeks
gestation in 3 women and pregnancy termination due to
trisomy 21 in 1 woman). Baseline demographic characteristics
are summarized in Table 1. Cardiac conditions of the study
population are listed in Table 2. According to the modiﬁed
World Health Organization classiﬁcation of maternal cardiac
risk in pregnancy, 17 (13%), 71 (56%), 36 (28%), and 3 (2%)
women were in modiﬁed World Health Organization categories
I, II, III, and IV, respectively.28 None of the women studied
were cyanotic. Forty-three women (34%) had signiﬁcant
valvular stenosis or regurgitation. There were no women in
this study with severe tricuspid stenosis or severe pulmonary
stenosis.20 In women with mixed valve disease, classiﬁcation
was based on the most hemodynamically relevant lesion. In
total, 64% (n=81/127) had congenital disease as their
primary lesion. In 57% (n=72/127), the mother had undergone prior intervention on the primary cardiac lesion,
consisting of the following: closure of an intracardiac shunt
(n=12), valve replacement or repair (n=31, of which 10
patients had a mechanical valve prosthesis inserted), repair of
complex congenital lesion (n=21), ablation or implantable
cardioverter deﬁbrillator for ventricular tachycardia (n=3),
pacemaker implantation (n=4), or coronary stenting (n=1).
Signiﬁcant left or right ventricular systolic dysfunction was
present in 9 pregnancies (7% of heart disease group).

Cardiac and Obstetric Imaging
All subjects (n=172) underwent cardiac output determination
at baseline (mean 134 weeks, range 6–25 weeks,
Table 1. Baseline Characteristics of Women With Heart
Disease and Healthy Controls
Heart Disease
(n=127)

Controls
(n=45)

P Value

Singleton pregnancies

124 (98%)

45 (100%)

0.57

Maternal age (meanSD), y

305

345

<0.001

Maternal age (18–35 y)

108 (85%)

29 (64%)

0.003‡

Obstetric risk factors*

29 (23%)

13 (29%)

0.42

Nulliparous

64 (50%)

23 (51%)

0.93

10 (8%)

0

0.065

Smoking
Comorbidities

†

18 (14%)

0

0.004

Study Population

Body surface area, meanSD

1.730.25

1.690.15

0.21

Consecutive women with heart disease were approached if
eligibility criteria were met. A total of 127 women with heart
disease and 45 healthy controls were enrolled and completed
the study. During the study period, 309 pregnant women with
heart disease were followed at our hospital, 171 were
excluded because they did not meet inclusion criteria, 7

Hemoglobin, g/L

1249

1268

0.22

DOI: 10.1161/JAHA.115.002414

*History of previous premature delivery or rupture of membranes, incompetent cervix,
cesarian delivery in a previous pregnancy; or presence of antepartum bleeding
>12 weeks gestation, febrile illness, premature labor, or uterine/placental abnormalities
during the current pregnancy.4
†
Diabetes mellitus, hypertensive, thyroid disorders, pulmonary disorders, or systemic
lupus erythematosus.6

Journal of the American Heart Association

4

ORIGINAL RESEARCH

Downloaded from http://ahajournals.org by on June 21, 2022

PI at the umbilical/uterine arteries as well as presence/
absence of bilateral notching, and changes in cardiac output
between baseline and third trimester. Serial change in cardiac
output during pregnancy was expressed in 2 ways: (1) D
cardiac output over time (slope) was an expression of change
in cardiac output (L) divided by the time interval between
measurements (weeks) (ie, [cardiac output third
trimester cardiac output baseline]/number of intervening
weeks), and (2) frequency (%) of pregnancies with a decline in
cardiac output between baseline and third trimester. A decline
in cardiac output was designated as a decrease in cardiac
output that exceeded the observer variability as delineated by
percentage error between the 2 measurements of cardiac
output. Umbilical or uterine Doppler parameters were classiﬁed as abnormal, signifying increased vascular resistance, if
the PI exceeded the 95% conﬁdence limits for gestational age
or if bilateral systolic notching of the Doppler spectrum was
evident.24,25
Candidate variables with a level of signiﬁcance P<0.10 on
univariate analysis were entered into a multivariable logistic
regression model examining the heart disease group.
A stepwise backwards elimination algorithm was utilized and
a signiﬁcance level P<0.05 was chosen for inclusion in the
multivariable model. After independent predictors were identiﬁed, these were then cross-validated in the heart disease
group by bootstrapping (Stata version 8.2, College Station,
TX) and were subsequently incorporated into a risk index
using previously described methodology.6 To calculate the
expected event rates, we determined the odds of occurrence
of a neonatal complication for each woman. This was
calculated using the logistic regression model derived from
our data. In our model, the beta coefﬁcient for each predictor
was rounded off in order to give equal weighting to each
predictor. The odds were then converted into an expected risk
of neonatal complications for each woman. The number of
women in each risk category (0, 1, and >1 predictors)
expected to have complications was then calculated. Discrimination (C-statistic) and calibration (Hosmer-Lemeshow
goodness of ﬁt) statistics were calculated. A multivariable
linear regression analysis examining possible predictors of
umbilical or uterine artery PI was also performed.
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Table 2. Antepartum Characteristics of Women With Heart Disease (n=127)

Primary Cardiac Lesion

n (%)

Prior Repair or
Intervention

Prior Cardiac
Events

Baseline
NYHA ≥2

Signiﬁcant AS,
MS, or PS*

Signiﬁcant AR, MR,
PR or TR

Intracardiac shunts

17 (13)

12

4

3

2

3

Valvular

47 (37)

Mitral/aortic

38

26

6

3

16

7

Pulmonic

9

5

1

1

—

2

17

2

—

1

7

Complex congenital

32 (25)

TOF/DORV
Complete TGA or ccTGA
Ebstein
Myocardial/coronary
DCM/CAD, or HCM
Arrhythmia

17
†

10

4

1

—

1

4

5

—

2

—

—

4

1

10

3

2

—

20 (16)
20
11 (9)

SVT or VT

7

3

7

—

—

—

Bradycardia

4

4

4

—

—

—

AR indicates aortic regurgitation; AS, aortic stenosis; ccTGA, congenitally corrected transposition of the great arteries (6 women); Complete TGA, complete or classic transposition of the
great arteries (4 women); DCM/CAD, dilated cardiomyopathy or coronary artery disease (17 women); DORV, double outlet right ventricle; HCM, hypertrophic cardiomyopathy (3 women);
MR, mitral regurgitation; MS, mitral stenosis; NYHA, New York Heart Association; PR, pulmonary regurgitation; PS, pulmonary stenosis; SVT, supraventricular tachycardia (4 women); TOF,
tetralogy of Fallot; TR, tricuspid regurgitation; VT, ventricular tachycardia (3 women).
*Moderate pulmonary stenosis observed in 2 women, 1 post Ross procedure within the homograft and 1 post arterial switch procedure; there were no women with severe pulmonary or
important tricuspid stenosis.
†
Rastelli procedure in 2 women and Jatene procedure in 2 women (women had complete TGA).
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interquartile range 11–15 weeks gestation), and again during
the third trimester (mean 323 weeks, range 27–39 weeks,
interquartile range 29–34 weeks gestation); postpartum
echocardiography was completed in 145 women (84%
of total) (mean 43 months, range 2–15 months, interquartile range 3–8 months following delivery). Twenty-seven
women with heart disease did not return for postpartum
echocardiography.
Baseline obstetric ultrasound data (mean 201 weeks
gestation) were available in 160 women (12 women with heart
disease unable to return during the speciﬁed time interval)
and third trimester data (mean 321 weeks gestation) were
available in 164 women (8 women with heart disease unable
to return during speciﬁed time interval). Of these, 151 studies
(94%) ≤26 weeks and 156 studies (95%) ≥27 weeks had
complete data for umbilical and uterine artery analyses.
Overall, of the women with heart disease, 111 (87%) had
complete data sets for analysis; baseline characteristics,
frequency of decline in cardiac output, and occurrence of
neonatal complications were not statistically different in those
with and without missing data.

controls (P=0.004). These 18 women experienced 20
complications consisting of the following: sustained tachyarrhythmia (supraventricular n=9 and ventricular n=1),
NYHA functional classiﬁcation decline ≥2 classes or
progression to NYHA class 4 disability (n=6), transient
ischemic attack (n=2), myocardial infarction attributed to
spontaneous right coronary artery dissection (n=1), and
endocarditis (n=1). Two women had multiple cardiovascular
events complicating the same pregnancy: 1 woman experienced a supraventricular tachyarrhythmia with concomitant worsening of NYHA class and a second woman had
atrial ﬂutter in addition to endocarditis. Sixteen of the 20
cardiovascular complications occurred in the antepartum
period. Obstetric complications occurred in 15 women,
consisting of gestational hypertension/preeclampsia in 9
women and premature rupture of membranes in 6 women;
obstetric event rates were not statistically signiﬁcant
between women with heart disease (n=11, 9%) and
controls (n=4, 9%). Frequency of gestational hypertension/preeclampsia was not statistically different in women
with and without neonatal complications.

Maternal Outcomes: Cardiovascular and
Obstetric

Fetal and Neonatal Outcomes

Cardiovascular complications occurred in 18 women with
heart disease (14%) but did not occur in any of the
DOI: 10.1161/JAHA.115.002414

There were no fetal or neonatal deaths in this cohort.
Neonatal complications occurred in 28 pregnancies (16%) and
were more frequent in women with heart disease as
Journal of the American Heart Association
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26

25

%
Pregnancies 20
15

18

14

10

2

5

1

1

5

0
Any Event

Low BW/SGA

Premature

IVH or RDS

Figure 1. Neonatal complication rates in women with heart
disease compared with healthy controls. Number of neonatal
events (n) are shown. BW indicates birthweight; IVH, interventricular hemorrhage; RDS, respiratory distress syndrome; SGA, smallfor-gestational-age birthweight.

compared with controls (n=26 or 21% versus n=2 or 4%,
P=0.01) (Figure 1). Neonatal complications in women with
heart disease were low birthweight/small-for-gestational-

Table 3. Characteristics of Heart Disease Group With and Without Neonatal Complications (n=127)

Downloaded from http://ahajournals.org by on June 21, 2022

Neonatal Complications (n=26)

No Neonatal Complications (n=101)

P Univariate

P Multivariable

Multiple gestation

3 (12%)

0

0.008*

—

Maternal age, y

305

305

0.92

—

Maternal age (18–35 y)

22 (85%)

86 (85%)

0.95

—

Obstetric risk factor†

11 (43%)

18 (18%)

0.008*

0.003

Nulliparity

16 (62%)

48 (48%)

0.20

—

Smoking

4 (15%)

6 (6%)

0.12

—

Comorbidity

4 (15%)

14 (14%)

0.76

—

9 (35%)

28 (28%)

0.49

—

Baseline NYHA >1

4 (15%)

6 (6%)

0.12

—

Baseline cardiovascular meds

6 (23%)

16 (16%)

0.39

—

ASA/warfarin/heparin

8 (31%)

15 (15%)

0.06*

—

12 (46%)

34 (34%)

0.24

—

Stenosis (AS, MS, or PS)

7 (27%)

15 (15%)

Regurgitation (any valve)

5 (19%)

22 (22%)

Baseline LV or RVEF <40%

2 (8%)

7 (7%)

1.00

—

Antepartum cardiovascular event

5 (19%)

10 (10%)

0.19

—

Absolute, g/L

11810

11812

0.69

Frequency (%) <100 g/L

1 (4%)

7 (7%)

1.0

Prior cardiovascular events

‡

Valve dysfunction at baseline

§

Hemoglobin in 3rd trimester

AS indicates aortic stenosis; ASA, aspirin; EF, ejection fraction; LV, left ventricular; MS, mitral stenosis; NYHA, New York Heart Association; PS, pulmonary stenosis; RV, right ventricular.
*Univariate predictors entered into the multivariable model.
†
History of previous premature delivery or rupture of membranes, incompetent cervix, cesarian delivery in a previous pregnancy; or antepartum bleeding >12 weeks gestation, febrile
illness, premature labor, or uterine/placental abnormalities during the current pregnancy.4
‡
Cardiovascular event deﬁned as pulmonary edema, stroke, sustained arrhythmia, death, reduction in NYHA by >2 function classes, or class 4 NYHA symptoms.6
§
Moderate or severe valve dysfunction.

DOI: 10.1161/JAHA.115.002414
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age (n=18), prematurity (n=14), and respiratory distress
syndrome/intraventricular hemorrhage (n=5). Neonatal
complications in control women were low birthweight
(n=1) and prematurity (n=1). Multiple complications in a
single infant were counted as a single outcome. The
neonatal event rate in the 10 mothers with mechanical
valves was 40% (n=4) compared with a neonatal event rate
of 19% in the remainder of the heart disease group; this
difference was not statistically signiﬁcant (P=0.12). On
univariate analysis, women in the heart disease group with
neonatal complications were more likely to have obstetric
risk factors, to have a multiple gestation, or to be on
anticoagulation/antiplatelet medications (Table 3). All
women with congenital cardiac disease underwent fetal
echocardiography; 1 fetus was diagnosed with a ventricular
septal defect antenatally and an additional 4 children were
diagnosed with shunt lesions on pediatric echocardiography
postnatally. Maternal cardiac World Health Organization
classiﬁcation was not associated with adverse neonatal
outcomes (P=0.43).

Controls n= neonatal events

Heart Disease
30
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Uteroplacental Doppler Flow Patterns

There were signiﬁcant within-group differences in cardiac
output measured at baseline versus third trimester in both
heart disease group (P<0.001) and controls (P=0.007).
However, there were no statistically signiﬁcant differences
in maternal cardiac output between heart disease and control
groups during or after pregnancy (baseline 5.3 versus 4.7 L/
min, P=0.083; third trimester 5.8 versus 5.1 L/min, P=0.17;
postpartum 4.6 versus 4.1 L/min, P=0.96); indexing cardiac
output to body surface area at baseline assessment also did
not reveal signiﬁcant differences between women with heart
disease and controls.
In the heart disease group, when absolute and indexed
cardiac output measurements were compared between
women with and without neonatal complications of pregnancy, no statistically signiﬁcant differences were noted, as
demonstrated in Table 4. However, when cardiac output
measurements were expressed as a change over time,
statistically signiﬁcant differences in cardiac output were
observed between those women with and without neonatal
complications. Speciﬁcally, negative D cardiac output with
progression of pregnancy was evident in those with
eventual neonatal complications, in keeping with a decrease
in cardiac output despite advancing gestation, as compared
with positive or ﬂat D cardiac output in those without
neonatal complications, as shown in Table 4. Overall, a
decline in cardiac output was observed in one third of
women with neonatal complications. Change in heart rate
was not signiﬁcantly different in women with neonatal
events as compared to those without (714 versus
99 bpm, P=0.22; change in stroke volume was of
borderline statistical signiﬁcance ( 4.415.5 versus
2.314.7 mL/beat, P=0.053).

Baseline Doppler ﬂow abnormalities were present within the
umbilical arteries in 7% (n=9/131) or uterine arteries in 13%
(n=19/149) of pregnancies. A statistically signiﬁcant decline
in mean PI for uterine arteries (P=0.001) and umbilical
arteries (P<0.001) was observed from baseline to third
trimester in both heart disease and control groups. When
comparing women with heart disease to controls, third
trimester mean PI values were signiﬁcantly different at the
uterine artery (0.870.23 versus 0.790.19, P=0.038) but
not at the umbilical artery (1.080.20 versus 1.02017,
P=0.14); baseline mean PI values did not differ signiﬁcantly
between the groups at either artery (uterine artery 1.060.30
versus 1.000.26, P=0.28; umbilical artery 1.370.20
versus 1.320.20, P=0.23).
However, when pregnancies in the heart disease group were
grouped according to presence or absence of neonatal
complications, umbilical artery ﬂow abnormalities were more
frequent in the third trimester in pregnancies where adverse
events in offspring occurred, as detailed in Table 5. Independent predictors of third trimester umbilical artery PI were NYHA
functional class ≥2 at baseline and D cardiac output with
progression of pregnancy; ≥moderate aortic or mitral stenosis
had borderline statistical signiﬁcance (Table 6). As both
umbilical PI and D cardiac output are continuous variables
and inversely related, negative D cardiac output (ie, reduction in
cardiac output with advancing pregnancy) corresponded to a
higher (ie, more likely to be abnormal) umbilical artery PI.

Prediction Rule for Neonatal Complications
Univariate candidate predictor variables of neonatal complications in the heart disease group (shown in Tables 3 through

Table 4. CO in Heart Disease Group With and Without Neonatal Complications (n=127)
Neonatal Complications (n=26)

No Neonatal Complications (n=101)

P Univariate

P Multivariable

CO: baseline, L/min

5.762.20

5.141.57

0.27

—

CO: 3rd trimester, L/min

5.742.40

5.841.79

0.65

—

CO: postpartum, L/min

4.682.29 (n=23)

4.511.31 (n=77)

0.66

—

CI: baseline, L/min per m2

3.291.17

3.000.86

0.26

—

3.281.26

3.421.05

0.50

—

2.711.23 (n=23)

2.620.69 (n=77)

0.45

—

CI: 3rd trimester, L/min per m
CI: postpartum, L/min per m

2

2

D CO per unit time, L/week

0.010.10

0.040.09

0.032*

0.037

D CO absolute, L

0.03+1.59

0.69+1.42

0.048*

0.039

17 (17%)

0.045*

0.017

Decline in CO, n (%)

9 (35%)

CI indicates cardiac index; CO, cardiac output.
*Variables entered into multivariable model.
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Table 5. Abnormal Uteroplacental Flow Patterns in the Heart Disease Group With and Without Neonatal Complications

Parameter

Timing of
Study

Pregnancies With Neonatal Complications
(%)†

Pregnancies Without Neonatal Complications
(%)†

P
Univariate

P
Multivariate

Abnormal uterine artery flow*

≤26 weeks

4/23 (17%)

10/81 (12%)

0.51

—

≥27 weeks

1/19 (5%)

8/81 (10%)

1

—

≤26 weeks

3/19 (16%)

4/69 (6%)

0.17

—

≥27 weeks

9/23 (39%)

8/88 (9%)

0.001†

<0.001

Abnormal umbilical artery
flow*

*Abnormal ﬂow patterns in the umbilical and uterine arteries deﬁned by presence of abnormal pulsatility index or bilateral notching on Doppler ﬂow interrogation.
†
Variables entered into multivariable model.

trimester umbilical artery Doppler variable did increase,
however, to 17.6 with multiple gestation pregnancies
excluded). As D cardiac output (L/week) between baseline
and third trimester correlated highly with decline in cardiac
output, only one of these could be evaluated in the same
model. However, when D cardiac output as a continuous
variable, either as an absolute change or corrected for time
interval between baseline and third trimester studies, was
evaluated in the multivariable model in place of dichotomous
decline in cardiac output, D cardiac output was also an

5) were entered into a multivariable logistic regression model.
The following 3 factors were found to be independent
predictors of neonatal complications: (1) any obstetric risk
factor (odds ratio 6.2, 95% CI 1.8–21.3, P=0.003), (2) decline
in cardiac output (odds ratio 4.3, 95% CI 1.3–14.6, P=0.017),
and (3) abnormal third trimester umbilical artery Doppler
(odds ratio 12.3, 95% CI 3.1–48.9, P<0.001). Exclusion of the
3 women with multiple gestation pregnancies did not result in
a change to the aforementioned predictors of adverse
neonatal outcomes (the odds ratio associated with the third

Table 6. Predictors of Abnormal Umbilical Artery Pulsatility Index in Heart Disease Group (≥27 Weeks Gestation)
Downloaded from http://ahajournals.org by on June 21, 2022

Pregnancies With Characteristic

Pregnancies Without Characteristic

Maternal Characteristic

n

Pulsatility Index (meanSD)

n

Pulsatility Index (meanSD)

P* Univariate

P Multivariable

Multiple gestation

3

0.870.25

105

1.090.20

0.15

—

Maternal age (18–35 y)

89

1.090.21

19

1.040.16

0.29

—

Obstetric risk factor4

26

1.090.16

82

1.080.22

0.49

—

Nulliparity

52

1.110.24

56

1.050.16

0.094*

—

Smoker

8

1.080.18

100

1.080.21

0.98

—

Comorbidity

16

1.130.28

92

1.070.19

0.47

—

29

1.100.23

79

1.070.19

0.56

—

10

1.220.29

98

1.070.18

0.12*

0.03

Prior cardiovascular events

6

NYHA ≥2 at baseline
Baseline cardiovascular medications

19

1.120.29

89

1.070.18

0.77

—

Antiplatelet/anticoagulant

22

1.110.24

86

1.070.19

0.68

—

≥Moderate AS or MS

13

1.170.28

95

1.060.19

0.12*

0.052

≥Moderate AR or MR

3

1.000.10

105

1.080.21

0.49

—

≥Moderate PR or TR

14

1.010.20

94

1.090.20

0.25

—

8

1.040.22

100

1.080.19

0.37

—

12

1.090.28

96

1.080.19

0.25

—

0.039*

0.008

LV or RVEF <40%
6

Antepartum cardiovascular event
D Cardiac output

†

AR indicates aortic regurgitation; AS, aortic stenosis; EF, ejection fraction; LV, left ventricle; MR, mitral regurgitation; MS, mitral stenosis; NYHA, New York Heart Association; PR,
pulmonary regurgitation; RV, right ventricle; TR, tricuspid regurgitation.
*Univariate predictors entered into the multivariable model.
†
Pulsatility index=[ 0.49Dcardiac output]+1.1; SD of regression=0.21, P=0.039.
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Through analysis of maternal and uteroplacental ﬂow patterns
at various stages of pregnancy, our study provides new
insights into the mechanistic underpinnings that contribute to
the development of adverse neonatal outcomes in pregnant
women with underlying heart disease. Importantly, we
demonstrated that inadequate augmentation of cardiac output during pregnancy and abnormalities in umbilical artery
Doppler ﬂow in the third trimester independently predicted

% Pregnancies

Event Rate
Expected

Observed

90
80
70
60
50
40
30
20
10
0
No Predictor

1 Predictor

> 1 Predictor

Figure 2. Observed adverse neonatal event rates following
pregnancy. Independent predictors of adverse neonatal events
(rates, %) are as follows: (1) any obstetrical risk factor, (2) decline in
cardiac output during pregnancy, and (3) abnormal umbilical artery
Doppler pattern in the third trimester. Ten women had >1 predictor,
speciﬁcally: 1 woman had all 3 predictors, 5 women had reduction
in cardiac output along with an obstetric risk factor, and 4 women
had reduction in cardiac output in addition to an abnormal umbilical
artery Doppler ﬂow.

DOI: 10.1161/JAHA.115.002414

neonatal complications. Furthermore, this study highlights the
utility of serial measurements of cardiac output to help
differentiate those women at risk for neonatal complications
from those who will have no major adverse events in
offspring. This study is also the ﬁrst to incorporate sequential
cardiac output measurements and umbilical artery Doppler
assessment into a risk index to stratify pregnant women with
heart disease into those at low, medium, or high risk for
neonatal complications.
Although inadequate cardiac output response has been
implicated as the mechanism responsible for the relationship
between poor maternal function class, left heart obstruction,
and fetal/neonatal complications in the population of pregnant women with heart disease,4,6,7 there have been no prior
studies examining antepartum and postpartum cardiac output
in this population. One of the key ﬁndings of our study is the
demonstration that inadequate augmentation of cardiac
output in pregnancies predicts neonatal complications,
thereby deﬁning one potential link in the pathophysiology of
adverse outcomes in women with heart disease. Importantly,
cardiac output paradoxically decreased from baseline to third
trimester in one third of the group with neonatal complications, in contrast to the expected increase in maternal cardiac
output of 30% to 50% by the beginning of the third
trimester.13 Our study demonstrates that 2 measurements
of maternal cardiac output early and late in pregnancy can be
used to detect those who are at increased risk for neonatal
complications, unlike measurements at a single time point
early or late in pregnancy, which were not found to be of
statistical signiﬁcance (Table 4). We attributed the absence of
between-group differences in baseline cardiac output to the
nature of our study group, wherein those with symptomatic or
severe cardiac conditions generally will have undergone
cardiac interventions prior to pregnancy, and women at very
high risk are counseled to avoid pregnancy altogether.
The complex interplay between abnormalities in placentation, maternal vascular health, and suboptimal fetal growth
has been well studied in the general population.29 Speciﬁcally,
placental disease has been implicated in the development of
preeclampsia and intrauterine growth restriction.30 However,
the relationship between placental abnormalities and neonatal
complications in women with heart disease has been only
recently described.16 Pieper and Balci and their colleagues
reviewed 209 women with congenital heart disease and found
that abnormalities in uteroplacental ﬂow patterns (measured
at the uterine and umbilical arteries) were more commonly
seen in pregnancies associated with adverse events in
offspring. Independent predictors of abnormal umbilical artery
resistance index at 32 weeks included tricuspid annular plane
systolic excursion, systemic atrioventricular valve regurgitation, and pulmonary atrioventricular valve regurgitation. Our
study extends their ﬁndings by demonstrating that third
Journal of the American Heart Association
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independent predictor of neonatal complications (Table 4).
The 3 aforementioned binary predictors (presence of obstetrical risk factors, decline in cardiac output, and abnormal third
trimester umbilical artery Doppler) were incorporated into a
risk index to predict the likelihood of neonatal complications
(Figure 2). Expected and observed event rates were as
follows: 0 predictors 5% expected and 7% observed, 1
predictor 30% expected and 24% observed, and >1 predictor
76% expected and 80% observed. The discrimination and
calibration statistics were 0.77 and P=0.26, respectively. The
above 3 binary independent predictors were cross-validated
using bootstrapping; the resultant odds ratios and discriminative statistics were similar to the original analysis. No
statistically signiﬁcant differences were found between
mothers with and without a mechanical valve with respect
to obstetric risk factors (40% versus 21%, P=0.24), decrease
in cardiac output with progression of pregnancy (40% versus
19%, P=0.12), or frequency of abnormal umbilical artery
Doppler waveforms in the third trimester (20% versus 15%,
P=0.65).
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Study Limitations
Although a single-center study can optimize reproducibility
and accuracy, the present study was not powered to
examine cardiac output and its effect on neonatal outcomes
in the context of speciﬁc lesions. On the other hand, we
would suggest that the generalizability of our study results is
enhanced by the prospective enrollment of a relatively large
population of women with heart disease. Despite its
prospective design with speciﬁc time points prescribed for
completion of study examinations, some patients were not
able to return to our center for speciﬁed antepartum and
postpartum imaging. Establishing baseline cardiac output
within the ﬁrst trimester of pregnancy was difﬁcult to
ascertain, given the usual timing for the ﬁrst obstetric visit
(often after completion of the ﬁrst trimester). Although
reported to be useful by others,16 resistance index in the
uterine and umbilical arteries was not utilized for our study
cohort because PI, a more widely utilized marker of placental
function, measures the entire waveform, and is the parameter routinely measured at our center.31 Finally, we
acknowledge that measurements of cardiac output and
umbilical artery Doppler interrogation in the third trimester
afford a relatively narrow window of opportunity for intervention between identiﬁcation of the high risk pregnancy
and diagnosis of complications in the neonate.

Implications for Clinical Practice and Future
Directions
We propose that surveillance in pregnancy be intensiﬁed in
those designated as “high risk” through this prediction model
in an attempt to mitigate adverse neonatal outcomes; the
clinical utility of this strategy, however, awaits further study.
Validation of our prediction model in larger populations and in
speciﬁc high risk subgroups would be of value and may
uncover additional relationships between maternal cardiac
adaptations and outcomes of offspring. Finally, further study
into the cost-effectiveness of our proposed model and the
possible utility of novel, noninvasive, bedside measurement of
cardiac output36 would likely be of interest.
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Rogers.
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trimester umbilical artery PI are associated with D cardiac
output, an important parameter that was difﬁcult to reliably
quantify in a multicenter study.16 In contrast to the study by
Pieper and Balci, where ﬂow abnormalities in both umbilical
and uterine arteries were related to complications in offspring,
we observed abnormal Doppler ﬂow in the umbilical arteries
alone. Our ﬁndings are in keeping with the belief that
umbilical artery ﬂows are the more direct reﬂection of
compromised fetal health, as compared with uterine artery
ﬂows, particularly when disease within the gas-exchanging
placental villi is present.31
Beyond the establishment of decline in cardiac output as
an independent predictor of adverse neonatal outcomes, our
study provides a unifying concept that integrates maternal,
placental, and fetal factors in determining pregnancy outcomes.32 To date, published literature examining the relationship between maternal cardiac output and placental blood
ﬂow has been limited to women with structurally normal
hearts.11,33 Our study focuses on cardiac output in women
with preexisting heart disease, thereby expanding the existing
knowledge base. Our observations support the notion that
“upstream” abnormalities in maternal cardiac output can
mediate “downstream” abnormalities in fetal ﬂow patterns,
and each of these factors is independently predictive of
complications in offspring. Speciﬁcally, we found that independent cardiovascular predictors of abnormal umbilical
artery ﬂow patterns included NYHA functional class ≥2,
signiﬁcant aortic or mitral stenosis, and inadequate augmentation of cardiac output.
In a recent review of established models to predict
outcomes of pregnancy (including the ZAHARA, CARPREG,
and World Health Organization risk scores), the authors
concluded that although maternal cardiovascular risk could
be accurately determined using validated scoring systems,
the known incremental risk in offspring could not be
adequately predicted with existing models.34 In contrast to
previous studies that have utilized baseline parameters at a
single point in time to predict adverse outcomes of
pregnancy, our study reveals that serial measurements at 2
time points during the antepartum period are necessary to
evaluate maternal–fetal interactions and the effect of these
on neonatal outcome. The obstetric risk factors, maternal
cardiac output measurements, and umbilical ﬂow patterns
found to be independent predictors of neonatal complications
in our cohort can be easily determined in clinical practice and,
pending further validation, may at some point be incorporated
into routine maternal care. Technology is now emerging to
allow for continuous noninvasive assessment of cardiac
output at the bedside without the need for echocardiography;
although these applications may have tremendous clinical
beneﬁt, they have yet to be studied in pregnant women with
cardiac disease.35
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